{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:13:51Z","timestamp":1762125231314,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2021.100659","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:54:38Z","timestamp":1639601678000},"page":"100659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere\u24c7 (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy"],"prefix":"10.1016","volume":"96","author":[{"given":"Farhad","family":"Shahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farahnaz","family":"Vafaeezadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafiseh","family":"Ansarinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Shahriari-Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ghazizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassanali","family":"Vahedian Ardakani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Ravanbod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharareh","family":"Seifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Foratyazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Asadollah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Rajabi Vahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Seghatoleslami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohsen","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Houshang","family":"Pourkhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davoud","family":"Babakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.curtheres.2021.100659_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.curtheres.2021.100659_bib0002","unstructured":"Uptodate.com; Docetaxel: Drug information. 2020. Uptodate."},{"key":"10.1016\/j.curtheres.2021.100659_bib0003","unstructured":"Cancer Tomorrow [Internet]. [cited 2022 Jan 1]. Available from: https:\/\/gco.iarc.fr\/tomorrow\/en."},{"key":"10.1016\/j.curtheres.2021.100659_bib0004","unstructured":"Institute for Health Metrics and Evaluation. [cited 2022 Jan 1]. Available from: https:\/\/www.healthdata.org\/institute-health-metrics-and-evaluation."},{"issue":"5","key":"10.1016\/j.curtheres.2021.100659_bib0005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.curtheres.2021.100659_bib0006","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review: The Epidemiology of CRPC","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100659_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1759-7714.12315","article-title":"Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study: Safety and efficacy of docetaxel","volume":"7","author":"Lim","year":"2016","journal-title":"Thorac Cancer"},{"issue":"10","key":"10.1016\/j.curtheres.2021.100659_bib0008","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non\u2013Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.curtheres.2021.100659_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/CAD.0000000000000265","article-title":"Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy","volume":"26","author":"Chanat","year":"2015","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100659_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ajco.12454","article-title":"Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I: Outcomes of the Asia-Pacific Breast Initiative-I","volume":"12","author":"Kim","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"34","key":"10.1016\/j.curtheres.2021.100659_bib0011","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.curtheres.2021.100659_bib0012","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non\u2013Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.curtheres.2021.100659_bib0013","article-title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer","volume":"11","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.curtheres.2021.100659_bib0014","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.curtheres.2021.100659_bib0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:58:22Z","timestamp":1757897902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X21000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":15,"alternative-id":["S0011393X21000370"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100659","relation":{},"ISSN":["0011-393X"],"issn-type":[{"type":"print","value":"0011-393X"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere\u24c7 (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100659"}}